Flexion – $77 Million Follow-On Offering

San Diego – July 7, 2016 – Cooley advised Flexion Therapeutics on its follow-on offering of 5,500,000 shares of common stock for gross proceeds of $77 million.

Flexion, which trades on The NASDAQ Global Market, is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, or OA, a type of degenerative arthritis.

Cooley advised Flexion on its IPO in February 2014 and its subsequent follow-on offering in December 2014.

The Cooley corporate and securities team advising Flexion included Tom Coll, Sean Clayton, Nicole van de Leuv, Terren O'Connor, Andrew Harline and Edmond Lay.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.